Atlas Trials

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Clinical trial NCT05193188 · UNKNOWN

Trial details

NCT number
NCT05193188
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Chondrosarcoma
Start date
2023-02-06
Primary completion
2025-03-31
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.